Gapping up
In reaction to strong earnings/guidance:
- JWN +9.3%, ARAY +7.8%, CRMT +7.7%
Other news:
- ATRS +6.1% (continued strength after confirming FDA approval of generic EpiPen utilizing VIBEX auto injector), DDS +1.1% (after closing 9% lower following earnings),
- KSS +1.0% (following JWN results)
- BMY +0.5% (receives FDA approval for Opdivo)
Analyst comments:
- ESPR +2.8% (upgraded to Buy from Neutral at Citigroup)
- VNOM +1.7% (upgraded to Buy from Hold at Stifel)
- ENB +0.9% (upgraded to Buy from Neutral at BofA/Merrill)
![]()